Compare IPSC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | RZLT |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.9M | 470.9M |
| IPO Year | 2021 | 2011 |
| Metric | IPSC | RZLT |
|---|---|---|
| Price | $2.20 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.25 | ★ $9.67 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $1.07 |
| 52 Week High | $2.97 | $11.46 |
| Indicator | IPSC | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 55.85 |
| Support Level | $2.14 | $2.91 |
| Resistance Level | $2.56 | $5.42 |
| Average True Range (ATR) | 0.19 | 0.31 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 25.53 | 31.55 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.